In Vitro Study: Effect of Cobalt(II) Chloride Against Dengue Virus Type 1 in Vero Cells

Teguh Hari Sucipto; Yovilianda Maulitiva Untoro; Harsasi Setyawati; Anisa Maharani; Novia Faridatus Sholihah; Siti Churrotin; Ilham Harlan Amarullah; Soegeng Soegijanto

doi:10.14499/indonesianjpharm30iss4pp316

In Vitro Study: Effect of Cobalt(II) Chloride Against Dengue Virus Type 1 in Vero Cells

Teguh Hari Sucipto, Yovilianda Maulitiva Untoro, Harsasi Setyawati, Anisa Maharani, Novia Faridatus Sholihah, Siti Churrotin, Ilham Harlan Amarullah, Soegeng Soegijanto

Abstract

Dengue virus (DENV) serotypes DENV-1 to DENV-4 are enveloped viruses that belong to the genus Flavivirus of the Flaviviridae. Dengue vaccine or antiviral has not yet been clinically approved for humans, even though there have been great efforts toward this end. Antiviral activity against DENV is needed to develop to be an alternative drug for DENV virus. Cobalt(II) chloride have been used in the treatment and prevention of diseases of humans since ancient times. The aim of this study is to investigate the antiviral effects and Cytotoxicity of Cobalt(II) chloride. This compound was further investigated for its inhibitory effect on the replication of DENV-1 in Vero cells. Antiviral activity and Cytotoxicity measured by WST-1 assay. The IC₅₀value of the Cobalt(II) chloride for DENV-1 was 0.38 μg/ml. The cytotoxicity of Cobalt(II) chloride to Vero cell suggest that the CC₅₀ value was 2.91 µg/ml The results of this study demonstrate the anti-dengue serotype 1 inhibitory activity of Cobalt(II) chloride was a high toxic compound.

Keywords

Cobalt(II) chloride, DENV-1, and Antiviral activity.

Full Text:

PDF

References

Aguiar M., Stollenwerk N., Halstead SB., 2016. The impact of the newly licensed dengue vaccine in endemic countries. PLoSNegl. Trop. Dis. 10: 1-23.

Burke DS., Monath TP., 2001. Flaviviruses. DM. Knipe, PM. Howley (Eds), Fields-Virology (4th Edition), Lippincott Williams & Wilkins, Philadelphia. pp. 852–921.

Chang EL., Simmers C., Knight DA., 2010. Cobalt Complexes as Antiviral and Antibacterial Agents. Pharmaceuticals. 3: 1711-1728.

Delehanty JB., Bongard JE., Thach DC., Knight DA., Hickey TE., Chang EL., 2008. Antiviral properties of cobalt(III)-complexes. Bioorg. Med. Chem. 16: 830–837.

Devlin JG., Brien T., Stephenson N., 1967. Case of Cobalt Poisoning. Brit. Med. J. 1: 544-545

Duckham JM., Lee HA., 1976. The Treatment of Refractory Anaemia of Chronic Renal Failure with Cobalt Chloride. Q. J. Med. 178: 277-294.

Dutta S., Celestine MJ., Khanal S., Huddleston A., Simms C., Arca JF., Mitra A., Heller L., Kraj PJ., Ledizet M., Anderson JF., Neelakanta G., Holder AA., Sultana H., 2018. Coordination of different ligands to copper(II) and cobalt(III) metal centers enhances Zika virus and dengue virus loads in both arthropod cells and human keratinocytes. Biochim. Biophys. Acta Gen. Subj. 1862: 40-50

Greenwood NN., and A. Earnshaw. 1997. Cobalt, Rhodium and Iridium, in Chemistry of the Elements. Butterworth-Heinemann, Oxford, England. pp. 1113-1143.

Gubler DJ., 2002. Epidemic dengue/dengue hemorrhagic fever as a publichealth, social and economic problem in the 21st century. Trends. Microbiol. 10: 100–103.

Halstead SB., 2008. Dengue Virus-mosquito Interactions. Annu. Rev. Entomol. 53: 273–291.

Lv J., Liu T., Cai S., Wang X., Liu L., Wang Y., 2006. Synthesis, structure and biological activity of cobalt(II) and copper(II) complexes of valine-derived schiff bases. J. Inorg. Biochem. 100: 1888–1896.

Sucipto TH., Churrotin S., Setyawati H., Kotaki T., Martak F., Soegijanto S., 2017. Antiviral Activity Of Copper(Ii)Chloride Dihydrate Against Dengue Virus type-2 In Vero Cell. Indonesian J. Trop. Infect. Dis. 6: 84-87

Woodland DL., 2015. Vaccines Against Dengue Virus. Viral Immunol. 28: 75.

Zandi K., Teoh BT., Sam SS., Wong PF., Mustafa MR., Abubakar S., 2011. Antiviral Activity of Four Types of Bioflavonoid Against Dengue Virus Type-2. Virol. J. 8: 1–11.

DOI: http://dx.doi.org/10.14499/indonesianjpharm30iss4pp316